Lomefloxacin

CHEMBL561 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
351.4 g/mol
LogP
-0.8
Phase
4

A fluoroquinolone antibiotic used to treat urinary tract infections and respiratory infections caused by susceptible bacteria. It works by inhibiting bacterial DNA gyrase and topoisomerase IV.

Peso molecular

351,3500 g/mol

LogP

-0,80

TPSA

72,90 Ų

Regla de cinco de Lipinski

Cumple

Mecanismo de acción

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21

InChI

InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)

Molecular Formula

C17H19F2N3O3

HBD / HBA

2 / 8

Enlaces Rotables

3

Átomos Pesados

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A fluoroquinolone antibiotic used to treat urinary tract infections and respiratory infections caused by susceptible bacteria. It works by inhibiting bacterial DNA gyrase and topoisomerase IV.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Lomefloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL561. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3948. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.